Associated Papers
PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X et al.
Journal of Cancer Research and Clinical Oncology, 2024
38466449 (PubMed )
Supplement: 432_2024_5626_MOESM11_ESM.xls › Sheet1
Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer.
Boström M et al.
Nature Communications, 2022
36396655 (PubMed )
Supplement: 41467_2022_34746_MOESM10_ESM.xlsx › Supplementary_Data_7
Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.
Wong JKL et al.
Nature Communications, 2022
35013316 (PubMed )
Supplement: 41467_2021_27792_MOESM3_ESM.xlsx › Figure_5a-c
TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer.
Zhang Z et al.
Frontiers in Cell and Developmental Biology, 2021
34917611 (PubMed )
Supplement: DataSheet1.ZIP › original_data › 5.BRCA_clinical › 3.Survival › BRCA_________.xlsx › Sheet2
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 8
A microscopic landscape of the invasive breast cancer genome.
Ping Z et al.
Scientific Reports, 2016
27283966 (PubMed )
Supplement: srep27545-s1.xls › suppl_table_1_IDC_histologic_gr
Comprehensive molecular portraits of human breast tumours.
Unknown Author
Nature, 2012
23000897 (PubMed )
Supplement: NIHMS393293-supplement-2.xls › SuppTable1
Select a paper to view details